REGN vs RSSS · P/E 14, rev $14.34B vs P/E 15, rev $49.1M
Regeneron Pharmaceuticals Inc (REGN) versus Research Solutions Inc (RSSS) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Research Solutions Inc (RSSS) is a software - application company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported RSSS revenue for 2025-06-30 was $49.1M. Net income was $1.3M. Revenue was up 9.9% from 2024-06-30 to 2025-06-30. RSSS currently screens at market cap $74.9M and trailing P/E 14.9.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. RSSS currently screens at market cap $74.9M and trailing P/E 14.9.
Not investment advice. Open the REGN and RSSS stock pages for the full models.
Not investment advice.